At the news
? MIXEDIMPACT 6/10 CLUSTER filed Aug 6, 2026 at 16:35 ET
United Therapeutics CEO Martine Rothblatt and EVP Paul Mahon collectively sold ~$490K in open-market shares within two days of the company's Q2 2026 earnings release, which showed a 2% YoY revenue miss ($783.3M vs. $804.6M consensus) but an EPS beat ($7.27 vs. $6.86). The sales follow option exercises and represent a small fraction of market cap, but the timing, right after a mixed earnings report with declining Tyvaso sales, raises watchfulness.
- CEO Rothblatt sold 4,895 open-market shares on Aug 5, 2026, for ~$2.5M (including sales after option exercises).
- EVP Mahon sold 8,300 open-market shares on Aug 6, 2026, for ~$4.3M (including sales after option exercises).
- Total open-market sales in cluster: ~$6.8M, representing 0.03% of $22.6B market cap, trivial proportionally.
- Q2 2026 revenue of $783.3M missed consensus by ~2.7% (down 2% YoY); EPS of $7.27 beat by 5.9%.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access